• Medicine
  • Published 2017

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

@inproceedings{Len2017SyntheticLS,
  title={Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL},
  author={Theresa E. Le{\'o}n and Tanya Rapoz-D'Silva and Sunniyat Rahman and Michael Magnussen and Nadine Farah and Jos{\'e} Afonso Guerra-Assunç{\~a}o and Rajeev Gupta and Elisabeth P. Nacheva and Javier Herrero and David C. Linch and Marc R Mansour},
  year={2017}
}
Loss of function mutations of Enhancer of Zeste (Drosophila) homolog 2 (EZH2), the enzymatic component of Polycomb Repressive Complex 2 (PRC2), are particularly frequent in the early T cell precursor (ETP) subtype of T cell Acute Lymphoblastic Leukaemia (T-ALL), and have been associated with chemotherapy-resistance and a poor prognosis. There is thus a need to identify novel treatment strategies for this subgroup of patients. We hypothesized that inactivation of EZH2 in T-ALL cells induces… CONTINUE READING